Main uses and therapeutic indications

Cardular is a medication containing the active substance doxazosin, which belongs to a group of medicines known as alpha-1 adrenoceptor antagonists. It is primarily used to manage specific cardiovascular and urological conditions by relaxing smooth muscle tissue in the blood vessels and the prostate.

Treatment of high blood pressure

Cardular is indicated for the treatment of hypertension (high blood pressure). It works by relaxing the walls of the blood vessels, allowing blood to pass through more easily. This mechanism helps to lower systemic blood pressure. It may be used as a standalone treatment or in combination with other types of antihypertensive medications, such as diuretics, beta-blockers, calcium antagonists, or ACE inhibitors.

Treatment of benign prostatic hyperplasia

Cardular is also used to treat the clinical symptoms of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. In patients with BPH, the medication helps to:

• Relax the muscle in the prostate and the exit of the bladder.
• Improve urinary flow.
• Alleviate symptoms such as the frequent need to urinate or a weak urinary stream.

Benefits and clinical effects

Cardiovascular benefits

In patients with hypertension, the primary benefit of treatment is the reduction of blood pressure levels, which is a key factor in reducing the long-term risk of cardiovascular complications. The medication provides a gradual reduction in blood pressure, typically maintaining its effect over a 24-hour period.

Urological benefits

For individuals with an enlarged prostate, the medication provides symptomatic relief. By improving the dynamics of urine flow, it enhances the quality of life for patients experiencing discomfort or difficulty with urination. Clinical effects on urinary flow are often observed shortly after starting the treatment.

Regulatory References

1. NIH DailyMed overview

Eligibility for Cardular (Doxazosin) — Official Regulatory Information

Cardular is officially established for use in adults (18 years and over), but regulatory bodies worldwide define specific populations who must not use the medicine or require special caution.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known hypersensitivity to doxazosin or other quinazolines; those with a history of orthostatic hypotension; and nursing mothers, as use is contraindicated during lactation by some authorities.
	Use is also contraindicated in BPH patients presenting with anuria, overflow bladder, or concurrent complications like upper urinary tract congestion or bladder stones.
Age-related Eligibility	Use in children and adolescents (under 18 years) is not recommended because safety and efficacy have not been established. Older adults (geriatric patients) can use the medicine but require close supervision.
Condition-specific Limitations	Use in patients with severe hepatic impairment is not recommended due to a lack of clinical experience. Caution is required in patients with mild or moderate hepatic impairment.
	Patients with Benign Prostatic Hyperplasia (BPH) symptoms must be screened to rule out prostate cancer before treatment initiation.

Connection to the overall eligibility profile: Regulatory documents primarily establish eligibility within the adult population, while defining absolute prohibitions based on existing medical conditions, such as hemodynamic instability or certain complicated urological states. Use in specific populations, like pregnant women, is only permitted when the potential benefit is determined to outweigh the potential risk.

The official regulatory documentation for Cardular defines its interaction profile based on two primary categories: pharmacokinetic (PK) and pharmacodynamic (PD) interactions.

Interaction Type	Official Regulatory Statement
Pharmacokinetic (PK)	Doxazosin is a substrate of the CYP3A4 enzyme. Co-administration with strong CYP 3A4 inhibitors (such as Itraconazole or Clarithromycin) may result in an increase in the systemic exposure of Doxazosin. A minor increase in drug exposure was noted with Cimetidine.
Pharmacodynamic (PD)	Doxazosin may cause additive blood pressure lowering effects when co-administered with PDE-5 inhibitors (Sildenafil, Tadalafil, Vardenafil) or other antihypertensives (e.g., Beta-Blockers, ACE Inhibitors). Conversely, co-administration with NSAIDs may reduce the antihypertensive effect.

This PD interaction with PDE-5 inhibitors leads to specific regulatory constraints, as official labels recommend a minimum 6-hour time interval between the intake of Doxazosin and a PDE-5 inhibitor to manage the risk of orthostatic hypotension. Official labels also advise caution in patients with mild hepatic impairment because exposure to Doxazosin has been observed to increase by approximately 40% in this population, and use in severe hepatic impairment is not recommended. Doxazosin has been demonstrated to have no effect on the protein binding of tested drugs such as Warfarin or Digoxin.

How Cardular Works

Cardular is a selective antagonist (blocker) of the alpha-1 adrenergic receptors (alpha1). The drug acts by binding to these receptors, which are primarily expressed on the smooth muscle cell membranes of the peripheral vasculature and the genitourinary system. This molecular interaction prevents the binding of natural sympathetic neurotransmitters, such as norepinephrine, thereby disrupting the sympathetic signal that promotes muscle contraction.

In the vasculature, this blockade prevents vasoconstriction, promoting peripheral vasodilation which reduces systemic vascular resistance and results in a decrease in pressure throughout the circulatory system. Concurrently, the inhibition of alpha1 receptors in the smooth muscle of the prostate, prostatic capsule, and bladder neck reduces the tonic tension in this region. This muscular relaxation decreases the physical constriction and outflow resistance in the lower urinary system, leading to an altered state of muscular activity within this tract.

Cardular (Doxazosin) is administered orally in either immediate-release (IR) or extended-release (ER) tablet forms. The official usage protocol is based on once-daily administration and a gradual titration phase to ensure standardized application of the medicine.

---

Official Dosing and Titration

Therapy begins with a low initial dose which is then gradually increased over several weeks. The exact regimen depends on the formulation and the specific condition being managed.

Indication	Initial Dose	Titration Interval (Approx.)	Maximum Daily Dose
Hypertension (IR)	1 mg once daily	1–2 weeks	16 mg once daily
BPH (IR)	1 mg once daily	1–2 weeks	8 mg once daily
BPH (ER)	4 mg once daily	3–4 weeks	8 mg once daily

---

Administration Specifics and Constraints

The extended-release tablet must be swallowed whole and must not be chewed, cut, crushed, or divided, as this disrupts its designed delivery mechanism. While the IR tablet can be taken without reference to meals, the ER formulation is specified to be taken with breakfast. Furthermore, blood pressure monitoring is required following the first dose and any subsequent dose increase as part of the procedural protocol.

Population-Specific Use

Labeled use generally indicates that no dose adjustment is necessary for patients with renal impairment. However, use requires caution in individuals with mild-to-moderate hepatic impairment, and it is generally not advised in severe impairment. If therapy is discontinued for several days, the official instruction mandates that the patient restarts the regimen using the initial low starting dose.

Research evidence / Overview of studies for Cardular

1. Evidence for use in Lower Urinary Tract Symptoms (LUTS) and BPH

Research has focused on Randomized, Double-Blind, Placebo-Controlled Trials (RCTs) exploring initial measurements of change in LUTS symptoms and functional measures. These short-term studies were supplemented by Long-Term Open-Label Extension Studies that applied in research contexts involving fluctuating or unstable symptoms. The studies examined measurements of outcomes related to physical discomfort using patient-reported symptom scales (such as the IPSS) and also monitored functional measures like maximum urinary flow rate.

The studies report how symptoms evolved in the observed populations, highlighting changes measured during the study period in both patient symptom scores and objective flow rates. Studies reported that a significant placebo response rate was observed during the short-term evaluation of symptoms, meaning many participants reported a favorable change in symptoms even when taking an inactive substance. The documented symptom change in trials may not consistently align with a major change in the patient's perceived discomfort, and existing studies provide limited insight into the long-term clinical significance of the observed changes.

---

2. Evidence for use in Chronic High Blood Pressure (Hypertension)

Cardular was studied for the management of high blood pressure through a research base of Randomized, Placebo-Controlled Trials and Pooled Analyses from multiple studies. Research has also explored its use in large-scale, Active-Controlled Comparative Trials against specific comparator agents. Studies monitored outcomes related to systemic or functional imbalance by evaluating Systolic and Diastolic Blood Pressure reduction in both standing and supine positions, and they examined measures of Systemic Vascular Resistance.

The research highlights changes measured during the study period in blood pressure when compared to placebo and other studied medications. Regulatory documents have noted a peak-to-trough variation in the measured blood pressure effect, suggesting the level of impact may differ depending on the time elapsed since the dose was administered. The clinical relevance and long-term impact of the observed small shifts in metabolic markers, such as cholesterol, are not fully established.

---

3. Long-Term Studies and Durability of Response

Studies observing responses over defined time intervals have included Long-Term Open-Label Extension Studies. For BPH, the research record includes observation periods extending up to four years for symptomatic and functional measurements. For high blood pressure, large comparative trials involved a median follow-up of over three years. Long-term cardiovascular outcome data for use of the medicine alone in the general hypertensive population is not fully established.

Common questions about Cardular (FAQ)

---

Q: Is Cardular a generic drug, or only available as a brand name?

A: Cardular is the brand name for the active ingredient, Doxazosin. According to official product information, Doxazosin is available as a generic drug in the immediate-release tablet form, in addition to the brand-name products (Cardura and Cardura XL).

---

Q: What are the contraindications for Cardular use?

A: Regulatory documents state that use is prohibited for patients with a known severe allergy (hypersensitivity) to Doxazosin or similar medicines called quinazolines, those with a history of low blood pressure upon standing (orthostatic hypotension), and nursing mothers. Additionally, for treating BPH, use is contraindicated in patients with complicated urological issues such as anuria (not producing urine), overflow bladder, or upper urinary tract congestion.

---

Q: How is Cardular removed or metabolized by the body?

A: The official product information indicates that Doxazosin is extensively processed in the liver, a process known as metabolism. This metabolism is primarily carried out by the CYP 3A4 enzyme. After metabolism, most of the dose is ultimately eliminated from the body via the feces.

---

Q: How often do I need to take Cardular (once or twice daily)?

A: Official regulatory dosing protocols for all approved indications, including treating high blood pressure (hypertension) and BPH, are based on a once-daily administration schedule. This applies to both the immediate-release and extended-release formulations.

---

Q: Are there any dietary restrictions while taking Cardular (Doxazosin)?

A: The official regulatory instructions specify that the extended-release formulation of Cardular is to be taken with breakfast. For the immediate-release formulation, while food may slightly affect its absorption, these changes are not generally considered to be clinically significant.

---

Q: Is Cardular safe to take during pregnancy?

A: Official information states there are no adequate and well-controlled studies regarding the use of Cardular in pregnant women. Doxazosin use during pregnancy is permitted only when the potential benefit is determined by a healthcare provider to outweigh the potential risks to the fetus, as safety in this population has not been definitively established.

How to Store and Dispose of Cardular? (Doxazosin)

The official storage and disposal requirements for Cardular are defined by government regulatory agencies to maintain drug stability and ensure safety.

Official Storage and Handling

Requirement Type	Official Regulatory Statement
Temperature Limit	Do not store above 30°C.
Protection	Store in the original package or outer carton.
Child Safety	Keep out of the reach and sight of children.
Handling Rule	Prolonged-release tablets must be swallowed whole; do not chew, divide, cut, or crush.

Disposal Instructions

Official labeling requires that unused or expired Cardular be disposed of according to local requirements for medicinal products. The product is not classified as an environmental hazard and requires no special hazardous-waste procedures.